Brainstorm Cell Therapeutics Revenue and Competitors

Claim your profile



Total Funding



Estimated Revenue & Valuation

  • Brainstorm Cell Therapeutics's estimated annual revenue is currently $7.5M per year.(i)
  • Brainstorm Cell Therapeutics's estimated revenue per employee is $202,703
  • Brainstorm Cell Therapeutics's total funding is $51.6M.

Employee Data

  • Brainstorm Cell Therapeutics has 37 Employees.(i)
  • Brainstorm Cell Therapeutics grew their employee count by 0% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

BrainStorm (OTC.BB: BCLI) is an emerging company developing stem cell therapeutic products based on breakthrough technologies. BrainStorm\'s core technology, NurOwn™, was developed through a collaboration between prominent neurologist, Prof. Eldad Melamed, Head of Neurology of the Rabin Medical Center and member of the Scientific Committee of Michael J. Fox Foundation for Parkinson\'s Research and expert cell biologist Dr. Daniel Offen, at the Felsenstein Medical Research Center of Tel-Aviv University.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Brainstorm Cell Therapeutics News

2022-04-20 - MiNK Therapeutics (NASDAQ:INKT) versus Brainstorm Cell ...

MiNK Therapeutics (NASDAQ:INKT) versus Brainstorm Cell Therapeutics (NASDAQ:BCLI) Financial Survey. Posted by admin on Apr 24th, 2022.

2022-04-17 - Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by ...

As a group, equities research analysts predict that Brainstorm Cell Therapeutics will post -0.87 earnings per share for the current fiscal year.

2022-03-22 - BrainStorm Cell Therapeutics Announces Full Year 2021 Financial ...

Brainstorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating...

2021-11-15 - BrainStorm Cell Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update

NEW YORK, Nov. 15, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced financial results for the quarter ended September 30, 2021, and provided a corporate update. "We made strong progre ...

2021-11-15 - BRAINSTORM CELL THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)

Company Overview BrainStorm Cell Therapeutics Inc. is a leading biotechnology company committed to the development and commercialization of best-in-class autologous cellular therapies for the treatment of neurodegenerative diseases including: Amyotrophic Lateral Sclerosis ("ALS", also known as ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding